A Phase 2/3, Multicenter, randomized, double-blind, placebo-controlled, study to evaluate the safety and efficacy of Alpha-! Antitrypsin for the Prevention of GVHD
Clinical Trial Grant
Awarded By
CSL Behring LLC
Start Date
February 15, 2019
End Date
February 14, 2025
Awarded By
CSL Behring LLC
Start Date
February 15, 2019
End Date
February 14, 2025